IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART

Journal of Clinical Investigation

Volumn 115, Issue 1, 2005, Pages 128-137

  Wang, Feng Xiang ^a   Xu, Yan ^a   Sullivan, Julie ^a   Souder, Emily ^a   Argyris, Elias G ^a   Acheampong, Edward A ^a   Fisher, Jaime ^a   Sierra, Maria ^b   Thomson, Michael M ^b   Najera, Rafael ^b   Frank, Ian ^c   Kulkosky, Joseph ^a,d   Pomerantz, Roger J ^a   Nunnari, Giuseppe ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHESTNUT HILL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; GLYCOPROTEIN GP 120; IMMUNOMODULATING AGENT; INDINAVIR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PHYTOHEMAGGLUTININ; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADJUVANT THERAPY; ARTICLE; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION CONTROL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PHYLOGENY; PRIORITY JOURNAL; PROVIRUS; SPECIES DIFFERENCE; T LYMPHOCYTE ACTIVATION; VIRUS ACTIVATION; VIRUS ENVELOPE; VIRUS GENE; VIRUS INDUCTION; VIRUS ISOLATION; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; BLOOD; CD4+ T LYMPHOCYTE; CELL CULTURE; CLASSIFICATION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LONG TERMINAL REPEAT; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GENE EXPRESSION REGULATION, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; PHYLOGENY; PHYTOHEMAGGLUTININS; PROVIRUSES; RNA, VIRAL; SPECIES SPECIFICITY; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 13744259064     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200522574     Document Type: Article

References (47)

1. Siliciano, J.D., et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
2. Chun, T.W., et al. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655.
3. Stellbrink, H.J., et al. 2002. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS. 26:1479-1487.
4. Kulkosky, J., et al. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-1411.
5. Emery, S., et al. 2000. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy inadult human immunodeficiency virus type 1 disease. J. Infect. Dis. 182:428-434.
6. Pandolfi, F., et al. 2000. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin. Immunol. 94:153-159.
7. Pett, S.L., and Emery, S. 2001. Immunomodulators as adjunctive therapy for HIV-1 infection. J. Clin. Virol. 22:289-295.
8. Tambussi, G., et al. 2001. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J. Infect. Dis. 183:1476-1484.
9. Namen, A.E., et al. 1988. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J. Exp. Med. 167:988-1002.
10. Benjamin, D., et al. 1994. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J. Immunol. 152:4749-4757.
11. Fernandez, E., et al. 1994. Establishment and characterization of cloned human thymic epithelial cell lines. Analysis of adhesion molecule expression and cytokine production. Blood. 83:3245-3254.
12. Watanabe, M., et al. 1995. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. 95:2945-2953.
13. Ryan, D.H., Nuccie, B.L., Ritterman, I., Liesveld, J.L., and Abboud, C.N. 1994. Cytokine regulation of early human lymphopoiesis. J. Immunol. 152:5250-5258.
14. Kroncke, R., Loppnow, H., Flad, H.D., and Gerdes, J. 1996. Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction. Eur. J. Immunol. 26:2541-2544.
15. Vella, A.T., Dow, S., Potter, T.A., Kappler, J., and Marrack, P. 1998. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 95:3810-3815.
16. Vella, A., Teague, T.K., Ihle, J., Kappler, J., and Marrack, P. 1997. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: STAT6 is probably not required for the effect of IL-4. J. Exp. Med. 186:325-330.
17. Boise, L.H., Minn, A.J., June, C.H., Lindsten, T., and Thompson, C.B. 1995. Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc. Natl. Acad. Sci. U. S. A. 92:5491-5495.
18. Komschlies, K.L., et al. 1994. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J. Immunol. 152:5776-5784.
19. Grzegorzewski, K.J., et al. 1995. Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7. J. Exp. Med. 181:369-374.
20. Carini, C., and Essex, M. 1994. Interleukin 2-independent interleukin 7 activity enhances cytotoxic immune response of HIV-1-infected individuals. AIDS Res. Hum. Retroviruses. 10:121-130.
21. Bui, T., Dykers, T., Hu, S.L., Faltynek, C.R., and Ho, R.J. 1994. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J. Acquir. Immune Defic. Syndr. 7:799-806.
22. Kaech, S.M., et al. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 12:1191-1198.
23. Napolitano, L.A., et al. 2001. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 7:73-79.
24. Llano, A., et al. 2001. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J. Virol. 21:10319-10325.
25. Smithgall, M.D., Wong, J.G., Critchett, K.E., and Haffar, O.K. 1996. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J. Immunol. 156:2324-2330.
26. Chene, L., et al. 1999. Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(-) CD3(+) thymocytes: a critical role for tumor necrosis factor and interleukin-7. J. Virol. 73:7533-7542.
27. Moran, P.A., Diegel, M.L., Sias, J.C., Ledbetter, J.A., and Zarling, J.M. 1993. Regulation of HIV production by blood mononuclear cells from HIV-infected donors: I. Lack of correlation between HIV-1 production and T cell activation. AIDS Res. Hum. Retroviruses. 9:455-464.
28. Scripture-Adams, D.D., Brooks, D.G., Korin, Y.D., and Zack, J.A. 2002. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76:13077-13082.
29. Soares, M.V., et al. 1998. IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of anaive repertoire. J. Immunol. 161:5909-5917.
30. Unutmaz, D., KewalRamani, V.N., Marmon, S., and Littman, D.R. 1999. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-1746.
31. Nugeyre, M.T., et al. 2003. L-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J. Immunol. 171:4447-4453.
32. Steffens, C.M., Managua, E.Z., Landay, A., and Al-Harthi, L. 2002. Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood. 99:3310-3318.
33. Armitage, R.J., Namen, A.E., Sassenfeld, H.M., and Grabstein, K.H. 1990. Regulation of human T cell proliferation by IL-7. J. Immunol. 144:938-941.
34. Welch, P.A., Namen, A.E., Goodwin, R.G., Armitage, R., and Cooper, M.D. 1989. Human IL-7: a novel T cell growth factor. J. Immunol. 143:3562-3567.
35. Fukui, T., et al. 1997. IL-7 induces proliferation, variable cytokine-producing ability and IL-2 responsiveness in naive CD4+ T-cells from human cord blood. Immunol. Lett. 59:21-28.
36. Yssel, H., Schneider, P.V., and Lanier, L.L. 1993. Interleukin-7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones. Int. Immunol. 5:753-759.
37. Borvak, J., et al. 1995. Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J. Immunol. 155:3196-3204.
38. Fry, T.J., et al. 2003. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood. 101:2294-2299.
39. Brooks, D.G., et al. 2003. Molecular characterization, reactivation and depletion of latent HIV. Immunity. 19:413-423.
40. Ducrey-Rundquist, O., Guyader, M., and Trono, D. 2002. Modalities of interleukin-7 induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J. Virol. 76:9103-9111.
41. Kulkosky, J., et al. 2003. Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo. Virology. 314:617-629.
42. Otero, M., et al. 2003. Peripheral blood dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res. Hum. Retroviruses. 19:1097-1103.
43. Toba, K., Winton, E.F., Koike, T., and Shibata, A. 1995. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y. J. Immunol. Methods. 182:193-207.
44. Wang, F.X., et al. 2002. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasispecies during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J. Infect. Dis. 185:608-617.
45. Casado, G., et al. 2003. Near full-length genome characterization of an HIV type 1 CRF05_DF virus from Spain. AIDS Res. Hum. Retroviruses. 8:719-725.
46. Thompson, J.D, Higgins, D.G., and Gibson, TJ. 1994. CLUSTAL W. improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
47. Saitou, N., and Nei, M. 1997. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.